RBC Capital analyst Douglas Miehm notes Valeant Pharmaceuticals (NYSE: VRX) scripts remain relatively flat: Derm NRx were up 0.9% week-over-week ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE